BridgeBio Pharma reported $154.2 million in fourth-quarter revenues and $502.1 million for full-year 2025, propelled by ATTRuby’s first full commercial year at $362.4 million in net product sales. In parallel, the company notched three late-stage wins in just over three months: positive Phase 3 readouts for infigratinib in achondroplasia (Propel 3), BBP-418 in LGMD2I/R9 (FORTIFY interim), and encaleret in ADH1 (CALIBRATE). BridgeBio plans two NDAs in the first half of 2026 (BBP-418, encaleret) and another in the second half (infigratinib), with U.S. launches anticipated from late 2026 into 2027. The company ended 2025 with $587.5 million in cash and augmented its balance sheet in January 2026 with $632.5 million of 2033 convertible notes.
The strategic question is whether BridgeBio’s hub-and-spoke model for genetically validated programs can now scale commercially without eroding capital efficiency. ATTRuby’s trajectory is encouraging: 7,804 unique patient prescriptions from 1,856 prescribers as of February 20, 2026, and 35% quarter-over-quarter net product revenue growth in Q4. Clinical positioning as the first near-complete transthyretin stabilizer (≥90%) with rapid onset could challenge incumbent stabilizers in transthyretin amyloid cardiomyopathy, but sustained advantage will hinge on outcomes resonance with cardiologists and on payers accepting that differentiation translates into fewer hospitalizations and deaths in real-world practice. Medical Affairs will need to lean into post-approval data, including upcoming OLE readouts at ACC, to reinforce the benefit story across subpopulations that carry disproportionate disease burden.
For payers and policymakers, BridgeBio’s 2026–2027 launch slate concentrates budget impact across three rare diseases with disparate care settings: pediatric endocrinology and genetics clinics for achondroplasia, neuromuscular centers for LGMD2I/R9, and metabolic/endocrine specialists for ADH1. Infigratinib’s oral regimen in achondroplasia, alongside statistically significant gains in height velocity and first-of-its-kind proportionality improvements, introduces a convenience and outcomes narrative versus established injectables. If approved, BBP-418 would be the first therapy for LGMD2I/R9, resetting the standard of care and resource utilization in a community accustomed to supportive management. Encaleret, as a targeted CaSR antagonist for ADH1, stands to benefit from rising diagnostic clarity, supported by >1,700 uniquely coded U.S. patients over two years—an early signal that payer identification and coverage pathways can be made launch-ready.
Competitively, the ATTR-CM market remains high-stakes and crowded, with stabilizers and gene-silencing approaches vying for share and guideline influence. In skeletal dysplasias, a credible oral alternative could redraw segment economics around specialty pharmacy distribution and adherence dynamics. For Commercial teams, BridgeBio’s prescriber breadth and patient persistence metrics suggest disciplined execution; the next test is payer durability as competitors pursue head-to-head data, class-based rebating, and outcomes contracts.
Financing choices underscore a broader industry playbook. BridgeBio is balancing revenue growth against sizable SG&A investment ($531.2 million in 2025) and ongoing net losses ($724.9 million for the year), while tapping converts and royalty capital to extend runway and smooth launch costs. Reauthorization of the FDA’s rare pediatric PRV program could provide optionality—either to accelerate review timelines or to monetize vouchers—mirroring a trend toward creative, less-dilutive funding to bridge multiple near-term launches.
The opportunity is clear: a path to six marketed products anchored by genetic validation and focused specialty engagement. The risk is equally clear: three near-simultaneous rare disease launches compress organizational bandwidth and payer negotiation cycles. As new data arrive and filings stack up through 2026, the question for competitors and investors alike is whether BridgeBio can convert scientific momentum into sustained market leadership before class effects, pricing pressure, and evidence requirements narrow its window of differentiation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
